GSK commences Phase III clinical trials to develop herpes zoster vaccine for the prevention of shingles
‘The commencement of the Phase III programme for our candidate herpes zoster vaccine is a significant milestone’, said Norman Begg, Chief Medical Officer of GSK Biologicals. ‘Shingles is an often debilitating condition for which there are limited treatment and prevention options. That is why progression into late stage development of our herpes zoster vaccine is an important milestone in ongoing efforts to potentially help address an important unmet need’.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.